Least-squares means (95% CI) of clinical assessments in patients with fibromyalgia syndrome (n = 325) by genotypes of guanosine triphosphate cyclohydrolase 1 single-nucleotide polymorphisms.
| Position* | Genotype | n† | FIQ | BFI | PCS | MCS | BDI | STAI-1 | STAI-2 |
|---|---|---|---|---|---|---|---|---|---|
| rs841 (C>T) | TT | 62 | 60.1 (55.4–64.0) | 6.7 (5.0–8.4) | 35.5 (33.6–37.4) | 33.8 (30.8–36.8) | 18.5 (15.8–21.2) | 49.2 (46.1–52.3) | 50.6 (47.8–53.5) |
| CT | 144 | 60.5 (57.4–63.6) | 6.7 (5.6–7.8) | 36.4 (35.2–37.7) | 32.5 (30.5–34.4) | 19.0 (17.3–20.8) | 49.6 (47.6–51.7) | 51.9 (50.0–53.8) | |
| CC | 119 | 58.6 (55.2–62.0) | 7.5 (6.2–8.7) | 35.6 (34.2–36.9) | 35.2 (33.0–37.3) | 18.7 (16.7–20.6) | 48.1 (45.9–50.3) | 50.3 (48.2–52.3) | |
| p†† | 0.70 | 0.62 | 0.59 | 0.20 | 0.93 | 0.58 | 0.50 | ||
| rs752688 (C>T) | TT | 60 | 57.1 (52.4–61.9) | 7.7 (6.0–9.4) | 36.1 (34.2–38.0) | 33.1 (30.1–36.1) | 18.1 (15.4–20.9) | 48.8 (45.7–52.0) | 50.9 (48.0–53.8) |
| CT | 153 | 61.3 (58.3–64.2) | 6.3 (5.2–7.4) | 36.2 (35.0–37.4) | 33.1 (31.2–35.0) | 18.8 (17.1–20.6) | 49.5 (47.5–51.5) | 51.5 (49.7–53.3) | |
| CC | 112 | 59.0 (55.6–62.5) | 7.5 (6.3–8.8) | 35.5 (34.1–36.9) | 34.9 (32.7–37.1) | 19.1 (17.1–21.1) | 48.4 (46.1–50.6) | 50.5 (48.4–52.6) | |
| p†† | 0.31 | 0.25 | 0.74 | 0.43 | 0.86 | 0.75 | 0.79 | ||
| rs4411417 (T>C) | CC | 57 | 57.2 (52.3–62.1) | 6.7 (4.9–8.4) | 35.8 (33.8–37.7) | 33.7 (30.5–36.8) | 17.3 (14.5–20.1) | 48.2 (44.9–51.4) | 50.0 (47.0–53.0) |
| TC | 155 | 61.2 (58.2–64.1) | 6.7 (5.7–7.8) | 36.3 (35.1–37.5) | 32.8 (30.9–34.7) | 19.0 (17.3–20.7) | 49.6 (47.6–51.5) | 51.7 (49.9–53.5) | |
| TT | 112 | 59.0 (55.5–62.5) | 7.5 (6.2–8.8) | 35.6 (34.2–37.0) | 35.0 (32.8–37.2) | 19.3 (17.3–21.3) | 48.6 (46.3–50.8) | 50.7 (48.6–52.8) | |
| p†† | 0.34 | 0.60 | 0.71 | 0.34 | 0.48 | 0.69 | 0.58 | ||
| rs3783641 (T>A) | AA | 14 | 59.7 (49.9–69.6) | 8.7 (5.1–12.3) | 36.1 (32.1–40.0) | 34.5 (28.2–40.8) | 20.5 (14.9–26.1) | 49.0 (42.5–55.6) | 51.4 (45.5–57.4) |
| TA | 77 | 59.7 (55.5–63.9) | 6.6 (5.1–8.2) | 36.6 (34.9–38.3) | 33.3 (30.6–36.0) | 17.8 (15.4–20.3) | 47.8 (45.1–50.6) | 50.9 (48.3–53.5) | |
| TT | 234 | 59.7 (57.3–62.1) | 7.0 (6.1–7.9) | 35.7 (34.8–36.7) | 33.8 (32.3–35.3) | 19.0 (17.6–20.4) | 49.3 (47.8–50.9) | 51.1 (49.6–52.5) | |
| p†† | 0.99 | 0.58 | 0.66 | 0.92 | 0.59 | 0.65 | 0.98 |
↵* Calculated from the translation start site.
↵† Missing data were excluded from the analyses: for rs4411417, n = 1; for FIQ, n = 1; for BFI, n = 5; for BD-I, n = 5; for STAI-1, n = 8; for STAI-2, n = 6.
↵†† p values from analysis of covariance, adjusted for age and sex. FIQ: Fibromyalgia Impact Questionnaire; BFI: Brief Fatigue Inventory; PCS: Physical Component Summary; MCS: Mental Component Summary; BDI: Brief Depression Inventory; STAI-1: State-Trait Anxiety Inventory-1; STAI-2, State-Trait Anxiety Inventory-2.